Sprycel price adjustment plan draws strong protest
Published: 2008-04-15 06:59:00
Updated: 2008-04-15 06:59:00
The government plan to adjust the insurance price of BMS Korea's Sprycel (dasatinib), an oral inhibitor of multiple tyrosine kinases, is drawing from leukemia patients, according to the Ministry of Health, Welfare and Family Affairs.
The ministry's insurance coordination committee failed to co...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
